An injectable nanoparticle generator enhances delivery of cancer therapeutics

Nature Biotechnology

Volumn 34, Issue 4, 2016, Pages 414-418

  Xu, Rong ^a,b,g   Zhang, Guodong ^a,g   Mai, Junhua ^a,g   Deng, Xiaoyong ^a,f,g   Segura Ibarra, Victor ^a   Wu, Suhong ^a   Shen, Jianliang ^a   Liu, Haoran ^a   Hu, Zhenhua ^a   Chen, Lingxiao ^a   Huang, Yi ^a   Koay, Eugene ^a,c   Huang, Yu ^a,f   Liu, Jun ^d   Ensor, Joe E ^a   Blanco, Elvin ^a   Liu, Xuewu ^a   Ferrari, Mauro ^a,e   Shen, Haifa ^a,e  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f SHANGHAI UNIVERSITY   (China)

^g University of South Dakota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; ENZYME INHIBITION; MAMMALS; NANOPARTICLES; SOLUTIONS; TUMORS;

BIOLOGICAL BARRIER; CANCER DRUG DELIVERIES; CANCER THERAPEUTICS; INDIVIDUAL COMPONENTS; MICROMETER SIZED PARTICLES; NANOMETER-SIZED PARTICLES; PERINUCLEAR REGION; POLY (LGLUTAMIC ACID);

DRUG DOSAGE;

CHLORPROMAZINE; DOXORUBICIN; DYNASORE; GENISTEIN; INJECTABLE NANOPARTICLE GENERATOR; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; ATOMIC FORCE MICROSCOPY; BREAST METASTASIS; CANCER THERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; MOUSE; NANOPORE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG SCREENING; FEMALE; HUMAN; NANOMEDICINE; NEOPLASMS; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYGLUTAMIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963680481     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3506     Document Type: Article

References (30)

1. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941-951 (2015).
2. Ferrari, M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 28, 181-188 (2010).
3. Michor, F., Liphardt, J., Ferrari, M. & Widom, J. What does physics have to do with cancer? Nat. Rev. Cancer 11, 657-670 (2011).
4. Lien, M. Y. et al. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res. 34, 7319-7326 (2014).
5. Verma, S., Dent, S., Chow, B. J., Rayson, D. & Safra, T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat. Rev. 34, 391-406 (2008).
6. Patel, H. M. & Moghimi, S. M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv. Drug Deliv. Rev. 32, 45-60 (1998).
7. Decuzzi, P. et al. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141, 320-327 (2010).
8. Lesniak, A. et al. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135, 1438-1444 (2013).
9. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
10. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
11. Tasciotti, E. et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3, 151-157 (2008).
12. Bae, Y., Fukushima, S., Harada, A. & Kataoka, K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Edn Engl. 42, 4640-4643 (2003).
13. Demaurex, N. pH Homeostasis of cellular organelles. News Physiol. Sci. 17, 1-5 (2002).
14. Padilla-Parra, S. et al. Quantitative imaging of endosome acidification and single retrovirus fusion with distinct pools of early endosomes. Proc. Natl. Acad. Sci. USA 109, 17627-17632 (2012).
15. Decuzzi, P., Pasqualini, R., Arap, W. & Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26, 235-243 (2009).
16. Godin, B. et al. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv. Funct. Mater. 22, 4225-4235 (2012).
17. van de Ven, A. L. et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control. Release 158, 148-155 (2012).
18. Wike-Hooley, J. L., Haveman, J. & Reinhold, H. S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2, 343-366 (1984).
19. Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979).
20. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
21. Fojo, T. & Menefee, M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 18 (suppl. 5), v3-v8 (2007).
22. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001).
23. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3-6 (2015).
24. Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
25. Shen, H. et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv. Healthc. Mater. 1, 84-89 (2012).
26. Alhareth, K., Vauthier, C., Gueutin, C., Ponchel, G. & Moussa, F. HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 887-888, 128-132 (2012).
27. Hurst, D. R. et al. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 69, 1279-1283 (2009).
28. Lu, X. & Kang, Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl. Acad. Sci. USA 106, 9385-9390 (2009).
29. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
30. McConnell, K. I. et al. Enhanced gene delivery in porcine vasculature tissue following incorporation of adeno-associated virus nanoparticles into porous silicon microparticles. J. Control. Release 194, 113-121 (2014).